Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010

ABSTRACT Chronic obstructive pulmonary disease (COPD) is the cause of substantial economic and social burden. We evaluated the temporal trends of hospitalizations from acute exacerbation of COPD and determined its outcome and financial impact using the National (Nationwide) Inpatient Sample (NIS) databases (2002–2010). Individuals aged ≥ 18 years were included. Subjects who were hospitalized with primary diagnosis of COPD exacerbation and those who were admitted for other causes but had underlying acute exacerbation of COPD (secondary diagnosis) were captured by International Classification of Diseases-Ninth Revision (ICD-9) codes. The hospital outcomes and length of stay were determined. Multivariate logistic regression was used to identify the independent predictors of inpatient mortality. Overall acute exacerbation of COPD-related hospitalizations accounted for nearly 3.31% of all hospitalizations in the year 2002. This did not change significantly to year 2010 (3.43%, p = 0.608). However, there was an increase in hospitalization with secondary diagnosis of COPD. Elderly white patients accounted for most of the hospitalizations. Medicare was the primary payer source for most of the hospitalizations (73–75%). There was a significant decrease in inpatient mortality from 4.8% in 2002 to 3.9% in 2010 (slope –0.096, p < 0.001). Similarly, there was a significant decrease in average length of stay from 6.4 days in 2002 to 6.0 days in 2010 (slope –0.042, p < 0.001). Despite this, the hospitalization cost was increased substantially from $22,187 in 2002 to $38,455 in 2010. However, financial burden has increased over the years.

[1]  Anne Holland,et al.  Telehealth reduces hospital admission rates in patients with COPD. , 2013, Journal of physiotherapy.

[2]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[3]  M. Malesker,et al.  Pharmacoeconomic evaluation of COPD. , 2000, Chest.

[4]  Angela E. Williams,et al.  Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. , 2006, Primary care respiratory journal : journal of the General Practice Airways Group.

[5]  T. Self,et al.  The clinical and economic burden of chronic obstructive pulmonary disease in the USA , 2013, ClinicoEconomics and outcomes research : CEOR.

[6]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[7]  G. Diette,et al.  In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. , 2003, Archives of internal medicine.

[8]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[9]  Cristianna A Abilez Evaluation of Health Care Cost and Utilization Project Data (HCUP) in Healthcare Research , 2013 .

[10]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[11]  G. Ogedegbe,et al.  Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.